[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE60015471D1 - Chinolin-4-yl-derivate - Google Patents

Chinolin-4-yl-derivate

Info

Publication number
DE60015471D1
DE60015471D1 DE60015471T DE60015471T DE60015471D1 DE 60015471 D1 DE60015471 D1 DE 60015471D1 DE 60015471 T DE60015471 T DE 60015471T DE 60015471 T DE60015471 T DE 60015471T DE 60015471 D1 DE60015471 D1 DE 60015471D1
Authority
DE
Germany
Prior art keywords
quinolin
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60015471T
Other languages
English (en)
Other versions
DE60015471T2 (de
Inventor
Alexander Alanine
Serge Burner
Bernd Buettelmann
Neidhart Marie-Paule Heitz
Georg Jaeschke
Emmanuel Pinard
Rene Wyler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of DE60015471D1 publication Critical patent/DE60015471D1/de
Publication of DE60015471T2 publication Critical patent/DE60015471T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/233Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • C07D215/46Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60015471T 1999-10-01 2000-09-26 Chinolin-4-yl-derivate Expired - Fee Related DE60015471T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99119539 1999-10-01
EP99119539 1999-10-01

Publications (2)

Publication Number Publication Date
DE60015471D1 true DE60015471D1 (de) 2004-12-09
DE60015471T2 DE60015471T2 (de) 2005-10-27

Family

ID=8239107

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60015471T Expired - Fee Related DE60015471T2 (de) 1999-10-01 2000-09-26 Chinolin-4-yl-derivate

Country Status (26)

Country Link
US (1) US6440995B1 (de)
JP (1) JP3523174B2 (de)
KR (1) KR100398561B1 (de)
CN (1) CN1181059C (de)
AR (1) AR025882A1 (de)
AT (1) ATE281436T1 (de)
AU (1) AU774363B2 (de)
BR (1) BR0004548A (de)
CA (1) CA2321324A1 (de)
CO (1) CO5200789A1 (de)
CZ (1) CZ20003575A3 (de)
DE (1) DE60015471T2 (de)
ES (1) ES2230017T3 (de)
HR (1) HRP20000639A2 (de)
HU (1) HUP0003861A3 (de)
ID (1) ID27525A (de)
IL (1) IL138777A0 (de)
MA (1) MA26752A1 (de)
NO (1) NO20004892L (de)
NZ (1) NZ507141A (de)
PE (1) PE20010648A1 (de)
PL (1) PL342876A1 (de)
PT (1) PT1088818E (de)
SG (1) SG164268A1 (de)
TR (1) TR200002831A2 (de)
ZA (1) ZA200005239B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6831087B2 (en) * 2001-11-09 2004-12-14 Hoffmann-La Roche Inc. Pyridine substituted isoquinoline derivatives
ATE309988T1 (de) * 2002-02-13 2005-12-15 Hoffmann La Roche Neue pyridin- und quinolin-derivate
US7648984B2 (en) * 2004-07-13 2010-01-19 Glaxo Group Limited Antibacterial agents
US20100267712A1 (en) * 2007-09-27 2010-10-21 The United States of America, as represented by the Secretary, Department of Health and Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
AU2015276537B2 (en) * 2014-06-16 2019-03-14 Fundacion Para La Investigacion Medica Aplicada Novel compounds as dual inhibitors of histone methyltransferases and dna methyltransferases
EP3206689B1 (de) * 2014-10-14 2021-12-08 La Jolla Institute of Allergy & Immunology Inhibitoren von niedermolekularer protein-tyrosinphosphatase und verwendungen davon
KR20170074178A (ko) * 2015-12-21 2017-06-29 제이엔씨 주식회사 중합성 액정 화합물, 조성물, 그 액정 중합막류 및 이들의 용도
CN105646462B (zh) * 2016-01-19 2019-04-05 河南大学 芸香宁碱衍生物、其制备方法及应用
EP3619210A4 (de) 2017-05-01 2020-12-02 Sanford Burnham Prebys Medical Discovery Institute Inhibitoren von niedermolekularer protein-tyrosinphosphatase (lmptp) und verwendungen davon

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE440008C (de) 1924-03-29 1927-05-04 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von Chinolinderivaten
US4560692A (en) 1984-07-18 1985-12-24 Hoffmann-La Roche Inc. 4-Piperidino-2-phenylquinolines
GB9125515D0 (en) 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
US5441963A (en) 1991-12-20 1995-08-15 Merrell Dow Pharmaceuticals Potentiation of NMDA antagonists

Also Published As

Publication number Publication date
ZA200005239B (en) 2001-04-16
JP3523174B2 (ja) 2004-04-26
CO5200789A1 (es) 2002-09-27
NO20004892D0 (no) 2000-09-29
CZ20003575A3 (cs) 2001-11-14
AR025882A1 (es) 2002-12-18
PE20010648A1 (es) 2001-06-13
TR200002831A3 (tr) 2001-04-20
HUP0003861A3 (en) 2002-09-30
AU774363B2 (en) 2004-06-24
CN1290698A (zh) 2001-04-11
PL342876A1 (en) 2001-04-09
SG164268A1 (en) 2010-09-29
ID27525A (id) 2001-04-12
NO20004892L (no) 2001-04-02
HUP0003861A2 (hu) 2001-10-28
IL138777A0 (en) 2001-10-31
ATE281436T1 (de) 2004-11-15
MA26752A1 (fr) 2004-12-20
AU6132400A (en) 2001-04-05
ES2230017T3 (es) 2005-05-01
US6440995B1 (en) 2002-08-27
DE60015471T2 (de) 2005-10-27
HRP20000639A2 (en) 2001-06-30
KR100398561B1 (ko) 2003-09-19
TR200002831A2 (tr) 2001-04-20
CN1181059C (zh) 2004-12-22
CA2321324A1 (en) 2001-04-01
PT1088818E (pt) 2005-03-31
NZ507141A (en) 2002-05-31
KR20010050738A (ko) 2001-06-15
BR0004548A (pt) 2001-05-29
JP2001097952A (ja) 2001-04-10
HU0003861D0 (en) 2000-12-28

Similar Documents

Publication Publication Date Title
NO20000885L (no) 4-Fenyl-pyridin-derivater
NO20021077L (no) Amino-triazolopyridin-derivater
ATE263748T1 (de) Admantan-derivate
ATE293104T1 (de) Thiazolylamid-derivate
IS6128A (is) 13-Metýl-erýþrómýsín afleiður
DK1187814T3 (da) 5-phenyl-pyrimidinderivater
ATE338021T1 (de) Substituierte 2-dialkylaminoalkylbiphenyl- derivate
NO20021803D0 (no) Isoksazolkarboksamid-derivater
ATE257148T1 (de) Propargyletherderivate
ATE374747T1 (de) Monofluoralkylderivate
DK1154988T3 (da) Mevinolinderivater
DK1218340T3 (da) 4-hydroxybiphenylhydrazid-derivater
ATE293592T1 (de) Resorcinderivate
DK1187815T3 (da) 4-phenyl-pyrimidinderivater
TR200002893A3 (tr) Kinolin-4-il türevleri II
DK1088818T3 (da) Quinolin-4-yl-derivater
DE60015471D1 (de) Chinolin-4-yl-derivate
DE60025348D1 (de) Ethansulfonyl-piperidin-derivate
NO20022867D0 (no) Syklopentenon-derivater
NO20020212D0 (no) 3-amino-2-benzyl-1-fenyl-propanderivater
PT1194401E (pt) Derivados de diacil-hidrazina
DE60001736D1 (de) 1-trifluorotmethyl-4-hydroxy-7-piperidinyl-aminomethylchroman-derivate
ATE269328T1 (de) 1-cycloalkylpyrazolyl-benzoyl-derivate

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee